Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.58 |
| ▸ | KLK7 | P49862 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18103838 | 1.00 | KLK5 (0.58) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL17731584 | 0.91 | CASP1 (0.54) | KLK5KLK7PPARACTSSSYK | |
| SCHEMBL9943562 | 0.88 | KLK5 (0.65) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL12585497 | 0.88 | KLK5 (0.65) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL84710 | 0.88 | PPARA (0.63) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL4370045 | 0.88 | KLK5 (0.65) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL344670 | 0.88 | PPARA (0.63) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL9943561 | 0.88 | KLK5 (0.65) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL344669 | 0.88 | PPARA (0.63) | KLK5KLK7PPARACTSSCACNA1B | |
| SCHEMBL10585294 | 0.88 | KLK5 (0.65) | KLK5KLK7PPARACTSSCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12171821-B2 | Toxoplasma gondii vaccine | WISCONSIN ALUMNI RESEARCH FOUNDATION (WARF) (US) | 2024-12-24 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20240026304-A1 | Method for Producing Stem Cell Clones Suitable for Induction of Differentiation into Somatic Cells | UNIV KYOTO (JP) | 2024-01-25 | — | — | US | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3296390-B1 | METHOD FOR PRODUCING STEM CELL CLONES SUITABLE FOR INDUCTION OF DIFFERENTIATION INTO SOMATIC CELLS | UNIV KYOTO (JP) | 2023-01-04 | — | — | EP | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | KLK5 1490/4885KLK7 702/4885PPARA 4333/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | KLK5 1490/4885KLK7 702/4885PPARA 4333/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | KLK5 1490/4885KLK7 702/4885PPARA 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.